News & Events » Media Stories
Macular Degeneration Therapy – December 20, 2010 – New Investment to Boost Gene Therapy Development
Monday, 20 December 2010
|
National Neurovision Research Institute (NNRI), the Foundation Fighting Blindness’ clinical trial support organization, announced today that one of its key partners, biopharmaceutical company Oxford BioMedica, has established a collaboration with sanofi-aventis, a major international pharmaceutical company, to develop and commercialize gene therapy treatments for vision-robbing retinal degenerative diseases that affect tens of millions of people around the world.
|









![Casting A Wide Net[work] | Presenting the interactive Foundation Fighting Blindness 2012 Annual Report 2012 Annual Report banner](https://www.blindness.org/images/banners/annual_report_box.jpg)


